Drugs Containing Excipient (Inactive Ingredient) CAPRYLIC ACID

Branded drugs containing CAPRYLIC ACID excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
GE Healthcare Inc	OPTISON	human albumin microspheres and perflutren	0407-2707	CAPRYLIC ACID	2028-05-09

Generic drugs containing CAPRYLIC ACID excipient

Company	Ingredient	NDC	Excipient
GE Healthcare Inc	human albumin microspheres and perflutren	0407-2707	CAPRYLIC ACID
BPL	albumin human	64208-2510	CAPRYLIC ACID
BPL	albumin human	64208-2512	CAPRYLIC ACID

Caprylic Acid Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: August 4, 2026

Caprylic acid is a low-cost, medium-chain fatty acid with pharmaceutical relevance in excipient systems, biologics processing, lipid formulations, and antimicrobial applications. Its standalone pharmaceutical market is small and generally not reported separately from broader medium-chain fatty acid, oleochemical, lipid excipient, or process-chemical markets. Revenue is driven less by the molecule’s composition-of-matter value than by GMP production, impurity control, documentation, regulatory qualification, and supply reliability.

The strongest commercial opportunity is in specialized biologics and lipid-based formulations. The principal financial risks are feedstock volatility, substitution by caprylate salts or other medium-chain fatty acids, and the limited pricing power of a commodity-derived molecule.

What is caprylic acid and how is it used in pharmaceutical products?

Caprylic acid, also known as octanoic acid, is an eight-carbon saturated fatty acid with the chemical formula C8H16O2 and CAS Registry Number 124-07-2. It is naturally present in coconut oil and palm kernel oil and is commercially produced through fatty-acid fractionation, hydrolysis, distillation, and purification of these feedstocks.

In pharmaceuticals, caprylic acid has several distinct roles:

Use area	Function	Commercial relevance
Lipid formulations	Oil-phase component, solubilizer, or fatty-acid excipient	Relevant to softgels, emulsions, and lipid delivery systems
Biologics processing	Selective precipitation or viral-reduction process aid	More valuable than bulk excipient use
Antimicrobial systems	Membrane-disrupting fatty acid	Usually part of a broader preservative or formulation strategy
Nutritional products	Medium-chain fatty-acid component	Larger than the strictly pharmaceutical-excipient segment
Salt derivatives	Caprylate or sodium caprylate formulation component	Often more practical than free caprylic acid in aqueous systems

Caprylic acid should be distinguished from sodium caprylate, potassium caprylate, calcium caprylate, and caprylic triglycerides. These materials have different physicochemical properties, regulatory classifications, specifications, and formulation uses.

What pharmaceutical formulations are protected by caprylic acid?

Caprylic acid is most commercially relevant in lipid and biologic formulations rather than conventional tablet excipients.

Lipid and softgel formulations

The free acid can contribute to solubilization and lipid-phase behavior. Its suitability depends on:

• Acid value and purity
• Peroxide and oxidation levels
• Residual solvents
• Water content
• Odor and color
• Compatibility with gelatin, capsule shells, surfactants, and active ingredients
• Stability under heat, light, and oxygen exposure

In softgels and lipid systems, caprylic acid may compete with medium-chain triglycerides, caprylic/capric triglycerides, oleic acid, mineral oils, and synthetic surfactants. The choice is usually formulation-specific rather than driven by a broad platform patent.

Biologics and plasma-derived products

Caprylic acid and caprylate salts have been used in protein purification and viral-reduction processes, especially in plasma fractionation. Their commercial value in this setting comes from process performance and validated manufacturing know-how.

A process using caprylic acid may precipitate selected proteins, reduce lipid-associated contaminants, or contribute to viral clearance. The relevant intellectual property usually covers process conditions, combinations with chromatography or filtration, and specific protein products. The molecule itself is not the protected asset.

Oral and topical products

Caprylic acid can be incorporated into oral, topical, and mucosal formulations where its fatty-acid properties are useful. Its low water solubility and strong odor can limit use. In many finished products, caprylate salts, glycerides, or other lipid excipients are easier to process.

How large is the caprylic acid pharmaceutical excipient market?

No major public company separately reports revenue for pharmaceutical-grade caprylic acid. Market reports typically combine caprylic acid with medium-chain fatty acids, fatty-acid derivatives, oleochemicals, nutraceutical ingredients, or specialty excipients.

The market structure is therefore best assessed through end-use economics:

Segment	Relative size	Margin profile	Growth driver
Food and flavor applications	High	Low to moderate	Consumer products and flavor systems
Nutraceuticals and sports nutrition	High	Moderate	Medium-chain lipid products
Industrial oleochemicals	High	Low	Surfactants, lubricants, coatings
Pharmaceutical excipient use	Low	Moderate to high	Formulation qualification and GMP supply
Biologics processing	Low volume	High relative value	Protein purification and viral clearance
Specialty derivatives	Moderate	Moderate to high	Caprylate salts, esters, and lipid systems

The pharmaceutical segment has higher unit economics than commodity food or industrial sales, but its absolute volume is small. A supplier can earn a premium through pharmaceutical documentation without obtaining drug-like pricing power.

What is driving caprylic acid market growth?

Growth in lipid-based drug delivery

Lipid formulations remain important for poorly soluble compounds, oral delivery systems, softgels, and certain controlled-release products. Caprylic acid can be used as a solubilizing or oil-phase component, although it competes with more established excipients.

Expansion of biologics manufacturing

The strongest specialized demand driver is the continued expansion of biologics, plasma-derived products, and protein purification. Caprylic-acid-based process steps can be attractive where they support viral reduction, impurity removal, or process simplification.

This demand is technically qualified and difficult to displace after incorporation into a validated manufacturing process. A change in supplier or grade can require comparability work, process validation, and regulatory documentation.

Demand for pharmaceutical-grade oleochemicals

Drug manufacturers increasingly require complete excipient supply-chain documentation, including traceability, elemental impurity controls, allergen declarations, residual solvent data, microbial limits, and change-notification commitments. These requirements support a premium for qualified grades.

Growth in Asia-Pacific manufacturing

Asia-Pacific is a major region for coconut, palm-kernel, oleochemical, generic-drug, nutraceutical, and contract-manufacturing activity. India and China are important demand centers, while Southeast Asia is important for feedstock and oleochemical production.

The region also has a wide range of supplier quality levels. Multinational drug manufacturers generally favor suppliers with validated facilities, quality agreements, audited supply chains, and stable regulatory support.

How does feedstock economics affect caprylic acid prices?

Caprylic acid is exposed to coconut oil and palm kernel oil economics. Feedstock availability, harvest conditions, export policies, shipping costs, energy prices, and demand for lauric oils all influence manufacturing costs.

The main cost factors are:

1. Coconut and palm-kernel feedstock prices.
2. Fractionation and distillation energy requirements.
3. Purification losses and yield.
4. Packaging and transport.
5. GMP testing and quality documentation.
6. Inventory requirements for qualified pharmaceutical supply.

Caprylic acid is usually produced within a broader fatty-acid manufacturing slate. Producers can adjust product allocation according to demand for capric acid, lauric acid, caprylic/capric triglycerides, surfactants, and other derivatives. This creates an integrated-asset advantage for large oleochemical manufacturers.

The financial trajectory is therefore likely to be stable in volume but cyclical in gross margin. Demand from pharmaceutical customers can reduce price volatility at the individual supplier level, but it cannot eliminate exposure to commodity feedstocks.

Which companies supply pharmaceutical-grade caprylic acid?

The relevant competitive group includes integrated oleochemical companies and specialty-ingredient distributors. Potential suppliers or supplier groups include:

• KLK OLEO
• Oleon
• Emery Oleochemicals
• Vantage Specialty Chemicals
• Wilmar International
• Pacific Oleochemicals
• Croda and specialty distribution partners in selected lipid and excipient categories
• Regional manufacturers in India, China, Southeast Asia, and Europe

Supplier participation must be evaluated by grade, facility, compendial status, GMP controls, regulatory support, and actual pharmaceutical customer qualification. A company that sells industrial or food-grade caprylic acid is not automatically a pharmaceutical-grade supplier.

The competitive advantage is based on:

• Consistent C8 specification
• Low odor and color
• Oxidative stability
• Traceability to feedstock
• GMP or excipient-quality manufacturing
• Multiple production sites
• Regulatory change control
• Technical support for formulation and process development

What FDA regulatory status applies to caprylic acid?

Caprylic acid is not regulated in the same way as an approved active pharmaceutical ingredient. Its regulatory treatment depends on its use.

FDA and excipient status

FDA’s Inactive Ingredient Database is the principal public reference for excipients used in approved drug products. An IID listing does not create a general approval for every grade, route, concentration, or formulation. It indicates historical use in approved products under specified conditions.

The regulatory assessment should address:

• Whether the exact substance is listed in the FDA IID
• Route of administration
• Maximum potency or concentration
• Dosage form
• Product-specific use
• Grade and specification
• Safety justification for a new use

FDA may require a sponsor to provide a safety assessment or submit an excipient justification when use exceeds established precedent or involves a new route.

USP-NF and compendial considerations

The United States Pharmacopeia-National Formulary and other pharmacopoeias may contain relevant monographs for fatty acids, oils, salts, or related materials. A compendial reference can simplify specification-setting but does not replace supplier qualification or finished-product compatibility testing.

European Union status

In the European Union, excipient acceptability is assessed through the marketing authorization process and relevant quality and safety guidance. Manufacturers must provide excipient control information, including supplier qualification and risk assessment. The European Medicines Agency’s excipient guidance is especially relevant for products where excipient safety information must appear in product information.

What patents protect caprylic acid pharmaceutical uses?

The caprylic acid molecule is old and cannot support a new composition-of-matter patent. Patent exposure is concentrated in downstream applications.

Patent category	Likely status
Caprylic acid composition of matter	Public-domain technology
General production of caprylic acid	Mostly mature and expired technology
Purification and fractionation	Potentially protected in narrow process claims
Protein purification	Active patents may cover specific proteins or process sequences
Viral inactivation	Possible claims covering conditions, combinations, and product classes
Lipid drug delivery	Possible formulation and method-of-use claims
Caprylate salts	Potentially protected for specific formulations or biologics
Finished drug products	Patents may cover the active ingredient, formulation, or use rather than the excipient alone

The key diligence question is whether a proposed product practices a patent claim directed to a specific formulation or manufacturing process. The presence of caprylic acid in a formulation does not, by itself, establish infringement.

Does caprylic acid have Orange Book or Paragraph IV risk?

Caprylic acid does not generally have a standalone Orange Book exclusivity profile because it is an excipient rather than a conventional approved drug active ingredient. Orange Book listings attach to approved drug products, not to commodity excipients as independent commercial products.

Paragraph IV litigation is therefore unlikely to target caprylic acid as an excipient. Risk can arise indirectly when:

• A generic drug uses a formulation covered by an Orange Book-listed patent.
• A biologic process uses a patented caprylic-acid purification step.
• A finished product claims a method involving caprylic acid or a caprylate salt.
• A supplier’s manufacturing process practices a third-party patent.

For small-molecule generics, the relevant patent analysis concerns the active ingredient, dosage form, method of use, and formulation. For biologics, process patents and regulatory exclusivity are more important than Orange Book mechanics.

How strong is the caprylic acid patent estate?

The core caprylic acid patent estate is weak because the molecule and basic production routes are longstanding. The application estate can be stronger in narrow technical fields.

Patent strength is highest where the claimed process provides:

• Measurable viral-clearance improvement
• Higher protein yield
• Lower aggregation
• Better stability
• Reduced processing steps
• A defined caprylic-acid concentration and pH window
• Integration with chromatography, filtration, or precipitation

Patent strength is lower where claims merely identify caprylic acid as one option in a broad list of fatty acids or excipients. Many such claims may face novelty, obviousness, enablement, or design-around challenges.

Trade secrets are commercially significant. Suppliers and biologics manufacturers may protect purification conditions, distillation parameters, impurity-removal methods, and quality-control procedures without relying exclusively on patents.

What manufacturing and IP barriers affect market entry?

Market entry is easier for industrial-grade production than for pharmaceutical supply. The key barriers are qualification and consistency.

A new pharmaceutical supplier may need to establish:

• Validated manufacturing and cleaning procedures
• Supplier and feedstock traceability
• Change-control systems
• Analytical methods for identity and purity
• Stability data
• Microbial and elemental impurity controls
• Residual solvent testing
• GMP or excipient-quality compliance
• Technical agreements with customers
• Long-term supply assurance

The qualification cycle can extend well beyond the time needed to manufacture the chemical. Once a supplier is approved, switching can be costly for the customer because the change may trigger formulation studies, comparability assessments, and regulatory submissions.

What generic entry scenarios exist for caprylic-acid-containing products?

There are four principal entry scenarios:

Commodity substitution

A customer replaces pharmaceutical-grade caprylic acid with another qualified supplier. This is the most common competitive threat and usually affects price and margin rather than patent rights.

Excipient substitution

A formulation developer replaces free caprylic acid with a caprylate salt, medium-chain triglyceride, capric acid, or another lipid excipient. This can eliminate demand if the replacement meets performance and regulatory requirements.

Formulation redesign

A generic or follow-on manufacturer designs around a patented formulation by changing concentration, excipient combination, dosage form, or manufacturing sequence.

Process replication

A biologics manufacturer reproduces a caprylic-acid-based purification or viral-reduction step. This creates potential process-patent exposure, but enforcement depends on claim scope and evidence of use.

What is the financial outlook for caprylic acid suppliers?

The financial outlook is best characterized as steady, specialized, and margin-sensitive.

Financial factor	Directional impact
Pharmaceutical qualification	Supports premium pricing
Commodity feedstock inflation	Compresses margins if contracts lag
Biologics demand	Supports specialized growth
Food and nutraceutical competition	Increases demand but limits pricing power
Supplier consolidation	Can improve scale economics
Caprylate and triglyceride substitution	Limits volume growth
Long-term supply agreements	Improve revenue visibility
Multi-site manufacturing	Reduces supply disruption risk

Revenue growth is more likely to come from higher-value grades, technical services, and biologics applications than from large increases in bulk pharmaceutical volume. Suppliers with integrated feedstock access and multiple end markets should have stronger earnings resilience than single-site specialty manufacturers.

Key Takeaways

• Caprylic acid is a mature C8 fatty acid with limited standalone pharmaceutical market reporting.
• Its pharmaceutical value is concentrated in qualified excipient grades, lipid formulations, and biologics processing.
• The molecule has no meaningful composition-of-matter patent moat.
• Application patents may cover protein purification, viral reduction, lipid delivery, or specific caprylate formulations.
• Orange Book and Paragraph IV risk generally applies to finished drug products, not caprylic acid as an independent excipient.
• Supplier qualification, GMP documentation, impurity control, and feedstock security are the main commercial barriers.
• Financial performance is tied to coconut and palm-kernel oil economics, specialty-grade premiums, and biologics demand.
• The most credible growth path is higher-value pharmaceutical and bioprocessing applications rather than bulk-volume expansion.

FAQs

Is caprylic acid an active pharmaceutical ingredient?

No. Caprylic acid is generally used as an excipient, formulation component, nutritional ingredient, or bioprocessing aid. Its regulatory treatment depends on the specific finished product and route of administration.

Is sodium caprylate the same as caprylic acid?

No. Sodium caprylate is the salt form of caprylic acid. It has different solubility, pH behavior, handling characteristics, specifications, and potential pharmaceutical uses.

Can caprylic acid be used in injectable drugs?

Use in an injectable product requires route-specific safety justification, formulation compatibility, and regulatory support. Historical use in one dosage form does not establish acceptability for injection.

Is caprylic acid a controlled substance?

No. Caprylic acid is not generally regulated as a controlled substance. Its handling remains subject to applicable chemical, occupational, transport, and pharmaceutical-quality requirements.

Which substitute is most likely to replace caprylic acid in a formulation?

The likely substitute depends on the function. Medium-chain triglycerides may replace it in lipid systems, while caprylate salts may replace it in aqueous protein-processing applications. Surfactants, capric acid, and other fatty-acid derivatives may also be used.

References

1. European Medicines Agency. (2019). Guideline on excipients in the label and package leaflet of medicinal products for human use. EMA.

2. International Council for Harmonisation. (2000). Q7: Good manufacturing practice guide for active pharmaceutical ingredients. ICH.

3. International Council for Harmonisation. (2023). Q9(R1): Quality risk management. ICH.

4. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. FDA.

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.

6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.